About me

I graduated in Clinical Biochemistry in July 2012 from Shiraz University of medical sciences and I hold a B.Sc. and an associate degree in medical lab sciences. 

Through my undergraduate education I became fascinated with biochemical and molecular mechanisms involved in Transformation of normal human cells into cancer cells. In addition, my work experiences in clinical laboratory in a cancer hospital of Isfahan encouraged me to pursue my career with a master in Clinical Biochemistry in order to do research and further investigations about fundamental molecular and genetic malfunctions behind cancer diseases. There is an increasing trend for breast cancer mortality in the world specially more developed countries. Hence, It is important to discover a reliable biomarker for detection of breast cancer and The underlying molecular mechanism of the disease needs to be better understood.

 My academic curriculum in undergraduate and postgraduate program provided me extensive theoretical and practical courses including Biochemistry, molecular and cell biology microbiology,hematology, Immunology,virology, Enzymology, Endocrinology, Lab research methods and tumor biology. Furthermore,I did my M.Sc. thesis project on "Study of p53 protein binding to DNMT1, HDAC1, MeCP2, BRCA1, hRad51 & UBE2Q1 in two breast cancer cell lines in vitro & in vivo". During this project, I learnt several key lab techniques.Parts of this research led to three journal papers and a conference presentation in an international congress.

After being awarded for Cavendish Scholarship, since January 2015, I am a doctoral researcher in Breast cancer research group in the Faculty of Life Science and Technology in the university of Westminster.


-Teaching assistant in practical modules for Biomedical students in the University of Westminster.( 2015 to present)

-Supervising postgraduates and undergraduates students for their project. ( 2015 to present)


Due to the heterogeneity and complexity of breast tumors some patients do not respond to their therapy. Breast cancer treatments have a significant personal and financial cost and current in vivo models such as the mouse avatar system have practical and theoretical drawbacks. Therefore, there is an urgent need for the creation of new in vitro technologies that may offer potential in determining the most appropriate treatment regimens for each patient.

to mimic tumor microenvironment, 3D in vitro tissue engineered constructs, will be formed from BC cell lines and patient samples through different techniques. Briefly, Artificial Cancer Mass (ACM) will be created and Then, controlled compression using RAFT 3D cell culture system will be applied , ACM will be placed in uncompressed collagen I as the extracellular matrix (ECM) containing stromal cells.

In the next step, the tumouroids will be cultured under static and flow conditions using Quasi vivo system. Then, tumoroids will be used to monitor the penetration and uptake of biological and chemotherapeutic drugs. 

This project will generate knowledge of the binding kinetics of drugs to cancer cell surfaces linked with drug penetration and uptake studies. These methods will be evaluated to determine if they may help to identify which drugs are appropriate for given patients in a time frame window between surgery and the start of chemotherapy, in the clinical setting.


For details of all my research outputs, visit my WestminsterResearch profile.